Does Keytruda's Dominance Make Merck & Co. a Buy Now? [The Motley Fool]
Merck & Company, Inc. (new) (MRK)
Last merck & company, inc. (new) earnings: 4/28 06:45 am
Check Earnings Report
US:NYSE Investor Relations:
investors.merck.com/home/default.aspx
Company Research
Source: The Motley Fool
Can an unstoppable cancer treatment help this big pharma stock outperform for your portfolio? Tumors that start in the lungs are relatively uncommon, but they still claim more lives than any others. Keytruda from Merck & Co. ( NYSE:MRK ) became the second member of its class the FDA approved to treat this underserved group a few years ago, and since then it's impressed oncologists and investors alike. Keytruda's success has already helped Merck deliver market-thumping gains in recent years, and the next act of its growth story could be even more exciting. Of course, Merck is a big company with lots of moving pieces, and some of the older ones aren't going in the right direction. Let's see if Keytruda has what it takes to offset aging product lines that have already started sliding backward. Image source: Getty Images. An important first Keytruda isn't the only drug that gets the immune system to keep hammering away at tumors by inhibiting PD-1, but right now
Show less
Read more
Impact Snapshot
Event Time:
MRK
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
MRK alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
MRK alerts
High impacting Merck & Company, Inc. (new) news events
Weekly update
A roundup of the hottest topics
MRK
News
- Scholz Gets Another Pharma Boost With New Merck KGaA Site [BNN Bloomberg (Canada)]BNN Bloomberg
- WebMD Ignite Unveils HealthHub Interactive to Support Health Plans' Clinical Programs [Yahoo! Finance]Yahoo! Finance
- Bristol-Myers posts Q1 beat despite growth headwinds [Seeking Alpha]Seeking Alpha
- Merck raises guidance as Keytruda sales jump 20% in Q1 [Seeking Alpha]Seeking Alpha
- Merck Raises Forecast as Sales of Its Cancer Immune Therapy Soar [BNN Bloomberg (Canada)]BNN Bloomberg
MRK
Earnings
- 4/25/24 - Beat
MRK
Sec Filings
- 4/25/24 - Form 8-K
- 4/11/24 - Form ARS
- 4/11/24 - Form DEFA14A
- MRK's page on the SEC website